ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PUB567

The Value of Intra-Operative PTH Assay during Parathyroidectomy in Dialysis Patients with Refractory Hyperparathyroidism

Session Information

Category: Mineral Disease

  • 1202 Mineral Disease: Vitamin D, PTH, FGF-23

Authors

  • Edon, Adeleye Annick, University of Kentucky, LEXINGTON, Kentucky, United States
  • Wang, Kevin, University of Kentucky, LEXINGTON, Kentucky, United States
  • Saxon, David, University of Kentucky, LEXINGTON, Kentucky, United States
  • Lima, Florence, University of Kentucky, LEXINGTON, Kentucky, United States
  • Sloan, David, University of Kentucky, LEXINGTON, Kentucky, United States
  • Sawaya, B. Peter Emile, University of Kentucky, LEXINGTON, Kentucky, United States
  • Mohamed, Amr El-Husseini, University of Kentucky, LEXINGTON, Kentucky, United States
Background

In dialysis patients with secondary and tertiary hyperparathyroidism (HPT), the correlation of intra-operative parathyroid hormone (ioPTH) measurement during parathyroidectomy (PTX) with long-term PTH level is unknown. The present study aims at evaluating the value of ioPTH measurements on long-term outcome of PTX in dialysis patients in a single center study.

Methods

The ioPTH was measured in 57 hemodialysis patients (33 females and 24 males) who underwent PTX between 2005 and 2015 because of refractory HPT. Near-total PTX was performed in 43 patients, total PTX in 15 patients (one patient underwent second PTX within 3 months because of failure of the first PTX). The ioPTH monitoring included 3 samples: pre-intubation (pre-ioPTH), 10- and 20-minute post PTX (10- ioPTH and 20-ioPTH). The patients were followed for up to 5 years (mean ± SD: 2.2 ± 2.1 years.

Results

The median (25th-75th percentile) pre-, 10- and 20-ioPTH levels were: 1447 pg/ml (969-2168), 143 pg/ml (78-244) and 112 pg/ml (59-153), respectively. There was no significant difference between 20-ioPTH and any subsequent PTH measurements (P=0.8, Figure). Sixteen patients (28%) were readmitted within 90 days due to significant hypocalcemia. One patient was readmitted for post-PTX hematoma evacuation. No patient required repeat PTX because of recurrent HPT.

Conclusion

The 20-ioPTH is a good indicator of long-term PTH values. Hypocalcemia is a common complication and the main reason for readmission after PTX. No patient required second PTX due to recurrent HPT.